Adenoviral vectors for gene replacement therapy

被引：53

作者：

Cao, HB ^{[1
]}

Koehler, DR ^{[1
]}

Hu, J ^{[1
]}

机构：

[1] Hosp Sick Children, Programme Lung Biol Res, Toronto, ON M5G 1X8, Canada

来源：

VIRAL IMMUNOLOGY | 2004年 / 17卷 / 03期

关键词：

D O I：

10.1089/0882824041857111

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Adenovirus-based vectors are promising vehicles for gene replacement therapy due to their ability to efficiently transduce a wide variety of proliferating and non-proliferating cells. Over the past decade, different versions of adenoviral vectors (Ads) have been developed. These vectors can be classified into two major categories, based on whether the viral coding sequences are partially (first or second-generation Ads) or completely deleted (helper-dependent or gutted Ads). Both types of Ads have been tested in a variety of gene delivery studies, and major obstacles to their clinical application have been identified. Currently, innate and adaptive host immune responses to Ads remain major challenges, limiting both the initial viral dose and the effectiveness of subsequent administrations. Recent developments in vector design and delivery methods have improved the potential of Ads for successful gene therapy application.

引用

页码：327 / 333

页数：7

共 66 条

[51] Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity [J].

Schiedner, G ;

Morral, N ;

Parks, RJ ;

Wu, Y ;

Koopmans, SC ;

Langston, C ;

Graham, FL ;

Beaudet, AL ;

Kochanek, S .

NATURE GENETICS, 1998, 18 (02) :180-183

[52] Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors [J].

Shi, CX ;

Hitt, M ;

Ng, P ;

Graham, FL .

HUMAN GENE THERAPY, 2002, 13 (02) :211-224

[53] In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor [J].

Smith, T ;

Idamakanti, N ;

Kylefjord, H ;

Rollence, M ;

King, L ;

Kaloss, M ;

Kaleko, M ;

Stevenson, SC .

MOLECULAR THERAPY, 2002, 5 (06) :770-779

[54]

Smith TAG, 1996, GENE THER, V3, P496

[55] Gene therapy progress and prospects: adenoviral vectors [J].

St George, JA .

GENE THERAPY, 2003, 10 (14) :1135-1141

[56] TNFα and IFNγ induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression [J].

Sung, RS ;

Qin, LH ;

Bromberg, JS .

MOLECULAR THERAPY, 2001, 3 (05) :757-767

[57] Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter [J].

Toietta, G ;

Koehler, DR ;

Finegold, MJ ;

Lee, B ;

Hu, J ;

Beaudet, AL .

MOLECULAR THERAPY, 2003, 7 (05) :649-658

[58] FK506 IMMUNOSUPPRESSION TO CONTROL THE IMMUNE-REACTIONS TRIGGERED BY FIRST-GENERATION ADENOVIRUS-MEDIATED GENE-TRANSFER [J].

VILQUIN, JT ;

GUERETTE, B ;

KINOSHITA, I ;

ROY, B ;

GOULET, M ;

GRAVEL, C ;

ROY, R ;

TREMBLAY, JP .

HUMAN GENE THERAPY, 1995, 6 (11) :1391-1401

[59] Successful expression of human factor IX following repeat administration of an adenoviral vector in mice [J].

Walter, J ;

You, QM ;

Hagstrom, JN ;

Sands, MS ;

High, KA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) :3056-3061

[60] Adenovirus technology for gene manipulation and functional studies [J].

Wang, YB ;

Huang, S .

DRUG DISCOVERY TODAY, 2000, 5 (01) :10-16

← 1 2 3 4 5 6 7 →